NCT02380677View on ClinicalTrials.gov

Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

October 4, 2017

Study Completion Date

October 4, 2017

Conditions
Advanced Solid Tumor Malignancy
Interventions
DRUG

CRLX301

Trial Locations (3)

19104

University of Pennsylvania, Philadelphia

27599

University of North Carolina at Chapel Hill, Chapel Hill

Unknown

MD Anderson, Houston

Sponsors
All Listed Sponsors
lead

NewLink Genetics Corporation

INDUSTRY

NCT02380677 - Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter